【摘 要】
:
Captopril (here abbreviated as Cpl), 1-[(2S)-3-mercaptp-2-methyl-1-oxypropyl]-L-proline (CgH15NO3S), an angiotensin converting enzyme inhibitor, has been successfully intercalated into magnesium alumi
【机 构】
:
Ministry of Education Key Laboratory of Science and Technology of Controllable Chemical Reactions, B
【出 处】
:
2005 WHTS3rd Annual Congress of International Drug Discovery
论文部分内容阅读
Captopril (here abbreviated as Cpl), 1-[(2S)-3-mercaptp-2-methyl-1-oxypropyl]-L-proline (CgH15NO3S), an angiotensin converting enzyme inhibitor, has been successfully intercalated into magnesium aluminum layered double hydroxides (denoted as Cpl-LDHs) by coprecipitation assembly technique.The X-ray diffraction spectra indicate that the reflections of Cpl-LDHs are sharp and symmetric, demonstrating the well-defined and single phase structure of LDHs-like compounds.The basal spacing d003 value was greatly expanded from 0.88 nm for NO3-containing LDHs to 1.42 nm for Cpl-LDHs,indicating the successful intercalation of Cpl between the host LDHs layers.The FT-IR spectrum of Cpl-LDHs shows that two bands at 1577 and 1402 cm-1 due to the antisymmetric and symmetric stretching mode of-CO2-, respectively,shift to lower wavenumbers, compared with free CO2-in Cpl (1748 and 1473 cm-1).It is suggested that the interlayer Cpl involves hydrogen bonding between-CO2-and hydroxyl group of LDHs layers [1].Based on ICP elemental analysis, the percentage of Cpl in LDHs is ca.31%.The in vitro release evaluation displays that the release rate and release percentages decrease obviously with increasing buffer pH.At pH 1.25, the release rate is very fast with ca.100% in 10 min.At pH 4.6, the release of Cpl is also fast during the first 1 min (65%), thereafter, a slower release is observed (95% after 55 min).At pH 7.4, 95% of Cpl released is not reached until to 100 min release time.The XRD, FT-IR, and ICP analyses for residues recovered from release media suggest that the release process may undergo gradual transition from dissolution mechanism to ion exchange one due to the increase in pH values of release media.
其他文献
一、社会责任:医院和媒体共同的目标医院和媒体都承担着共同的社会责任,这是一个我们双方都必须始终坚持的、不容动摇的目标。特别是在目前多元、多变、多样的社会中,我们必须按照大众的需求来提供社会需要并充分认可的服务内容和方式,当然我们也共同地会面对一些困惑和思考。二、媒体的独特性——传播、监督、引领功能媒体有其独特性,有传播、监督与引领功能。媒体要必须站在社会公众的立场上,对其他行业进行监督与褒扬,包括
国有大医院开展特需医疗服务的目标是赢得竞争优势,有条件地实现利益最大化。按照不同的竞争范围和层次,竞争态势基本可以表述为三种:产品大类中的竞争与合作,产品品类中的竞争与合作,品牌竞争中的竞争与合作。考虑到国有大医院提供特需服务较高的成本因素和顾客对医疗健康服务的需求特性,特需医疗服务的主要目标顾客群体具有的共同特点是收入较高且未加入我国的社会医疗保障体系,或社会医疗保障体系不能充分满足其以健康保护
Objective To study the anti-tumor effect and possible mechanism of anti-cancer bioactive peptide (ACBP) for the orthotopic transplantation human hepatocellular carcinoma tumor in nude mice.Methods The
β-Lactams can acylate serine residues of bacterial transpeptidases and, thus, results in arrest of cross-linking of peptidoglycans.Examples include penicillin N and cephalosporin C.Naturally occurring
We have developed a series of N-Salicylidene-based β-amino acids as chiral auxiliaries for chiral vanadyl(V) complex synthesis.These configurationally well-defined complexes have been examined for kin
At least 200 million people are infected by HBV worldwide.Most of them tend to develop chronic hepatitis B, which is prone to cause hepatocellular carcinoma.Patients with chronic hepatitis usually hav
Drug chirality is now a major theme in the design, discovery and development of new drugs [1].An analysis of the worldwide approved drugs according to chirality character (single enantiomers, racemate
The bifunctional enzyme aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase)/IMP cyclohydrolase (ATIC), catalyzes the penultimate and final steps in the de novo purine biosynthesis p
Large-scale mammalian cell culture platform consists of clone titer screening, clone robustness screening in serumfree suspension medium, in-house produced serum-free culture medium, and affordable ma
Dengue virus type 2 (DEN2) NS3 protease is required for the processing of the viral polyprotein and viral maturation.Therefore, the NS3 protease represents a promising target for antiviral drug design